This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.
Orforglipron is a small molecule rather than a peptide, which is the whole point: no SNAC absorption enhancer, no fasting window, no cold chain, and oral bioavailability in the tens of percent instead of around one. Phase 2 put it near 14.7% weight loss at 36 weeks on the top dose with a side-effect profile that looks like the injectables.
Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.
What would genuinely help is knowing whether a non-peptide oral agonist can match injectable exposure in practice, or whether the convenience is bought with a lower ceiling. If the honest answer is that nobody knows, that is a useful answer and I would rather have it.
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
SarahChen_PharmD said:Orforglipron is a small molecule rather than a peptide, which is the whole point: no SNAC absorption enhancer, no fasting window, no cold chain, and…
Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
SarahChen_PharmD said:Orforglipron is a small molecule rather than a peptide, which is the whole point: no SNAC absorption enhancer, no fasting window, no cold chain, and…
I read this differently from SarahChen_PharmD, on substance rather than tone. Small molecule does not automatically mean cheap. Price is set by what the market will bear and by patent life, not by cost of goods, and I would not assume the savings reach patients.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsShort answer first, then the reasoning. The manufacturing argument is the underrated one. Peptide synthesis capacity has been the binding constraint on this entire class, and a small molecule is made in ordinary chemical plants. If it holds up in phase 3, the supply and price picture changes more than the efficacy picture does.
DebRD_ATL said:Right, and the exception is worth naming rather than left implied, because the exception is where people get into trouble.
Same experience, arrived at from the opposite direction. Nothing to add that would improve it.